Back
FDA panel backs Replimune melanoma therapy after critical review triggers probe

FDA panel backs Replimune melanoma therapy after critical review triggers probe

An FDA advisory panel voted 10-3 to support Replimune’s RP1 melanoma therapy, and the agency is set to decide on the biologics application by Aug. 2 after earlier reviewers questioned the study’s reliability.

Fact Check
Replimune's official press release and independent reporting from BioPharma Dive both confirm the 10-3 advisory committee vote in favor of RP1, the August 2, 2026 FDA decision date, and that FDA reviewers had questioned the reliability/interpretability of the single-arm IGNYTE study. These corroborating primary and secondary sources fully support the claim's central facts. The 'probe' reference aligns with stockholder investigation announcements tied to the review controversy included in the input links.
    Reference: 12
Summary

An FDA advisory committee voted 10-3 that Replimune Group’s efficacy results for RP1, formally known as vusolimogene oderparepvec, are evaluable and clinically meaningful in advanced melanoma patients who progressed on prior anti-PD-1 therapy. The vote followed a contentious review process in which FDA briefing documents had questioned whether the single-arm IGNYTE study and its assessment methods reliably demonstrated benefit, criticism that helped send Replimune shares down $3.27, or 37.89%, in intraday trading on July 28, 2026. Replimune said the committee discussion focused on whether IGNYTE could provide a reliable determination of expected response rate and duration of response in the proposed population, and whether the observed responses suggested systemic antitumor activity attributable to RP1 when combined with nivolumab. The FDA’s target action date for the Class 1 resubmission of the biologics license application is Aug. 2, 2026. Bragar Eagel & Squire has said it is investigating potential securities-law claims on behalf of stockholders following the sharp share decline.

Terms & Concepts
  • single-arm IGNYTE study: A clinical trial testing one treatment regimen without a control group.
  • Biologics License Application: A formal submission companies use to seek FDA approval to market a biologic medicine.
  • anti-PD-1 therapy: A type of immunotherapy that blocks the PD-1 pathway to help the immune system attack cancer.